Recent commentary on Medtronic (MDT) has focused on its cardiac ablation, diabetes care and hypertension franchises, with the FDA approved Symplicity Spyral renal denervation system drawing attention as investors weigh differing short term earnings views.
See our latest analysis for Medtronic.
Medtronic’s recent 9.71% 1 month share price return contrasts with a share price decline of 15.69% year to date and a 1 year total shareholder return decline of 2.80%. This suggests momentum has picked up only recently as investors reassess its earnings and renal denervation story.
If you are considering how other health focused technologies are being priced, it can be useful to scan opportunities in AI driven healthcare by reviewing the 39 healthcare AI stocks
With Medtronic shares still below their recent highs and trading at a discount to some analyst targets and intrinsic value estimates, investors may need to consider whether this represents a reset that leaves potential upside on the table or if the market is already accounting for future growth.
Most Popular Narrative: 10.4% Undervalued
Medtronic’s narrative fair value of $90.37 versus the last close at $80.98 frames the stock as undervalued in this view and sets up a long-term, income-focused thesis according to Silvester.
Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.
Curious what sits behind that $90.37 fair value for Medtronic? The narrative leans on steady revenue expansion, disciplined margins and a future earnings multiple that assumes patient compounding over years, not quarters.
Result: Fair Value of $90.37 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Medtronic’s longer term share price decline of 25.32% over 5 years and the recent 5.55% 90 day pullback indicate that sentiment can turn against the stock.
Find out about the key risks to this Medtronic narrative.
Next Steps
If this Medtronic story seems mixed, take that as a cue to review the numbers yourself, compare against peers, and see the 6 key rewards.
Looking for more investment ideas beyond Medtronic?
If this Medtronic analysis sparked fresh questions, do not stop here. Broaden your watchlist now using targeted stock ideas that match your own risk and income preferences.
- Spot potential income pillars by reviewing companies in the 8 dividend fortresses that may help anchor a portfolio with substantial cash distributions.
- Hunt for potential value opportunities by scanning the 44 high quality undervalued stocks where solid fundamentals and attractive pricing come together.
- Prioritise resilience by assessing companies in the 71 resilient stocks with low risk scores that score well on financial strength and business stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com